0001667699-20-000001.txt : 20200715 0001667699-20-000001.hdr.sgml : 20200715 20200715122347 ACCESSION NUMBER: 0001667699-20-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200715 DATE AS OF CHANGE: 20200715 EFFECTIVENESS DATE: 20200715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Renibus Therapeutics, Inc. CENTRAL INDEX KEY: 0001667699 IRS NUMBER: 810872431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-349442 FILM NUMBER: 201028678 BUSINESS ADDRESS: STREET 1: 950 E. STATE HIGHWAY 114 STREET 2: STE-160 CITY: SOUTHLAKE STATE: TX ZIP: 76092 BUSINESS PHONE: 386-527-1071 MAIL ADDRESS: STREET 1: 950 E. STATE HIGHWAY 114 STREET 2: STE-160 CITY: SOUTHLAKE STATE: TX ZIP: 76092 D/A 1 primary_doc.xml X0708 D/A LIVE 0001667699 Renibus Therapeutics, Inc. 181 Grand Avenue Suite 225 SOUTHLAKE TX TEXAS 76092 817.722.5768 DELAWARE None None Corporation true 2015 Alvaro Guillem 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 Executive Officer Director Chairman of the Board, Chief Executive Officer D. Jeffrey Keyser 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 Executive Officer Director President, Secretary and Chief Operating Officer Henrik Rasmussen 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 Director Bhupinder Singh 181 Grand Avenue Suite 225 Southlake TX TEXAS 76092 Director Pharmaceuticals Decline to Disclose 06b true 0001667699-19-000001 2019-09-12 false true true false 0 Melior Capital Management GMBH None None None Baarerstrasse 12 Zug V8 SWITZERLAND 6300 MA MASSACHUSETTS true 35000000 19750184 15249816 false 18 116640 true 0 In addition, Recipient earned warrants to purchase equity in the issuer with an initial value equal to 4.0% of the aggregate number of securities issued to investors introduced to issuer by Recipient. 0 false Renibus Therapeutics, Inc. /s/ Alvaro Guillem Alvaro Guillem Chairman of the Board and CEO 2020-07-15